All Posts Tagged With: "ELN"
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant...
29Dec2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Gains – Earnings Miss Estimates
Acorda Therapeutics Inc. (ACOR) recorded adjusted earnings of 7 cents per share for the second quarter of fiscal 2011, compared with a loss of 18 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 12 cents per share. Higher revenues during...
4Aug2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Presents Encouraging Data
Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32). ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole). ...
1Jul2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Evenly Poised
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS)...
24Jun2011 | vitalstocks | 0 comments | Continued(MS) Merck KGaA to Withdraw Multiple Sclerosis Drug
Merck KGaA (MKGAF) recently announced its plans to withdraw the regulatory applications filed with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approval to market cladribine as a treatment for relapsing-remitting multiple sclerosis...
23Jun2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec and Partner Elan Announce EU Label Update for Tysabri
Recently, Biogen Idec, Inc. (BIIB) and partner Elan Corporation (ELN) announced that the European Commission (EC) has approved an update to the label for their multiple sclerosis (MS) drug Tysabri (natalizumab) in the European Union (EU). The updated label includes anti-JC Virus...
22Jun2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Gets Mixed Data on Ampyra
Acorda Therapeutics, Inc. (ACOR) recently reported an analysis of data on Ampyra (dalfampridine) at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. The analysis demonstrated improvements in walking ability of patients on Ampyra as measured by patient self-report...
16Jun2011 | vitalstocks | 0 comments | Continued(BJ) Company News for June 10, 2011 – Corporate Summary
• On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry & Technology. The acquisition will enhance and expand 3M’s product availability in the aerospace market • ...
14Jun2011 | vitalstocks | 0 comments | Continued(BJ) Company News for June 10, 2011 – Corporate Summary
• On Thursday, 3M Company (NYSE:MMM) said it has concluded an agreement to buy manufacturer of quick cure, aircraft sealants Advanced Chemistry & Technology. The acquisition will enhance and expand 3M’s product availability in the aerospace market • ...
10Jun2011 | vitalstocks | 0 comments | Continued(ALKS) Stock Market News for May 10, 2011 – Market News
After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited...
10May2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermesto Buy Elan Unit for $960 Million
Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately...
9May2011 | vitalstocks | 0 comments | Continued(ACOR) Acorda Therapeutics Reports Loss That Missed Expectations
Acorda Therapeutics Inc. (ACOR) posted a loss of 2 cents per share for the first quarter of fiscal 2011, compared with a loss of 56 cents in the year-ago period. The Zacks Consensus Earnings Estimate for the quarter was 18 cents per share. Despite increased revenues, higher operating...
8May2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Earnings Above Estimates on Multiple Sclerosis Drugs
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per...
26Apr2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Earnings Report Beats The Street
Biogen Idec (BIIB) reported first-quarter earnings per share of $1.42, 3 cents above the Zacks Consensus Estimate of $1.39 and well above the year-earlier figure of $1.04. Excluding the impact of stock-based compensation expense, first quarter 2011 earnings came in at $1.43 per...
23Apr2011 | vitalstocks | 0 comments | Continued(PDLI) PDL BioPharma Ramps Up Earnings – Settles Disputes
PDL BioPharma Inc. (PDLI) posted fourth quarter earnings of 20 cents per share, above the year-ago figure of 17 cents. Higher revenues boosted earnings in the quarter. Earnings per share were, however, a penny short of the Zacks Consensus Estimate of 21 cents. For full year 2010,...
7Mar2011 | vitalstocks | 0 comments | Continued(BIIB) Biogen Quarterly Earnings Report Beats by a Wide Margin
Biogen Idec (BIIB) reported fourth-quarter earnings per share of $1.41, well above the Zacks Consensus Estimate of $1.23 and the year-earlier figure of $1.18. Excluding the impact of stock-based compensation expense, fourth quarter 2010 earnings came in at $1.42 per share. Full...
1Feb2011 | vitalstocks | 0 comments | Continued(PDLI) PDL BioPharma Meets Earnings Forecast – Beats Revenue Forecast
PDL BioPharma Inc. (PDLI) posted third quarter earnings of 25 cents per share, in line with the Zacks Consensus Estimate, but below the year-ago figure of 29 cents. Earnings declined in the quarter, despite the increase in revenue, due to higher selling and general expenses. Quarterly...
17Nov2010 | vitalstocks | 0 comments | Continued(ELN) Elan Quarterly Report Matches Earnings Estimates
Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording a divestment gain of $107.7 million, which...
3Nov2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Beats Earnings Forecast by a Wide Margin
Biogen Idec Inc. (BIIB) reported third-quarter earnings per share of $1.33, well above the Zacks Consensus Estimate of $1.20 and the year-earlier figure of $1.09. Excluding the impact of stock-based compensation expense, third quarter 2010 earnings came in at $1.35 per share. Performance...
26Oct2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Delivered Earnings Surprises Over the Past Few Quarters
Biogen Idec Inc. (BIIB) is slated to announce its third quarter results on October 26. The Zacks Consensus Estimate is $1.20, well above the year-earlier earnings of $1.09. Second Quarter Highlights Biogen Idec Inc. reported second-quarter earnings per share of $1.27, well above...
25Oct2010 | vitalstocks | 0 comments | Continued(PDLI) PDL BioPharma Announces Third-Quarter Outlook
PDL BioPharma Inc. (PDLI) recently announced that it expects to generate third-quarter 2010 (ending September 30) revenue of $86.0 million, representing an increase of 20% over the year-ago revenue of $71.4 million. The increase is primarily attributable to higher sales of Avastin,...
7Sep2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Second Quarter 2010 Earnings Preview
Biogen Idec Inc. (BIIB) is set to announce its second quarter 2010 results on Tuesday, July 20, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter is $1.08 per share (with a downside of 0.93%), compared to the 73 cents per share earned in the...
19Jul2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Quarterly Report Shows Wider Loss
Medivation Inc. (MDVN) reported a loss of 51 cents per share in the first quarter of 2010, exceeding the Zacks Consensus Estimate of a loss of 42 cents and the year-ago loss of 19 cents. Lower revenues and higher expenses led to the higher loss. Revenues for the quarter were...
17May2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec’s Earnings Report Misses Consensus
Biogen Idec Inc. (BIIB) reported first-quarter earnings per share of $1.04, a cent above the year-ago figure of $1.03 but well below the Zacks Consensus Estimate of $1.12. Excluding the impact of stock-based compensation expense, earnings came in at $1.08 per share. Despite an...
21Apr2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Announces Workforce Reductions
Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and development activities related to dimebon and MDV3100. Medivation also announced the departure of its senior vice...
1Apr2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec’s Tysabri Against Teva’s Copaxone and Merck Serono/Pfizer’s Rebif
Biogen Idec (BIIB) and Elan Corporation, plc (ELN) recently announced that they have started enrolling patients for a phase IIIb head-to-head study between Tysabri and Teva Pharmaceuticals’ (TEVA) Copaxone and Merck Serono/Pfizer’s (PFE) Rebif. The randomized, rater-blinded,...
27Mar2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Reports Wider Fourth Quarter Loss
Medivation Inc. (MDVN) reported dismal results in the fourth quarter of 2009 with net loss coming in at 78 cents per share, wider than the Zacks Consensus Estimate of a net loss of 57 cents and the year-ago net loss of 26 cents. Despite full year revenues increasing to $69.3...
16Mar2010 | vitalstocks | 0 comments | Continued(MDVN) Medivation Shares Fall on Alzheimer’s Phase III Data
Medivation, Inc. (MDVN) shares fell 67% following the release of disappointing phase III results on lead pipeline candidate dimebon. The company, along with partner Pfizer, Inc. (PFE), suffered a huge setback when dimebon failed to achieve both its primary and secondary endpoints...
4Mar2010 | vitalstocks | 0 comments | Continued(PML) Stronger Label Warnings for Biogen Idec’s Tysabri
The US Food and Drug Administration (FDA) recently issued a notice on its website regarding the risk of developing progressive multifocal leukoencephalopathy (PML) with increased use of Tysabri. Tysabri, which is marketed by Biogen Idec (BIIB) and Elan Corp. (ELN), is approved...
1Mar2010 | vitalstocks | 0 comments | Continued(BIIB) Biogen Idec Beats Expectations and Guides Higher
Biogen Idec Inc. (BIIB) reported fourth quarter earnings per share of $1.18, beating the Zacks Consensus Estimate of $1.05. The company reported earnings of 91 cents in the year-ago period. Performance was driven by higher revenues and lower expenses. Revenues increased 5% to...
10Feb2010 | vitalstocks | 0 comments | Continued